![]() |
|
|
Vol. 56, Issue 6, 1254-1261, December 1999
Anatomisches Institut, Bayerische Julius-Maximilians-Universität, Würzburg, Germany
| |
Summary |
|---|
|
|
|---|
After site-directed mutagenesis, the organic cation transporter
rOCT1 was expressed in Xenopus laevis oocytes or
human embryonic kidney cells and functionally characterized. rOCT1
belongs to a new family of polyspecific transporters that includes
transporters for organic cations and anions and the
Na+-carnitine cotransporter. When glutamate was substituted
for Asp475 (middle of the proposed 11th transmembrane
-helix), the
Vmax values for choline, tetraethylammonium
(TEA), N1-methylnicotinamide, and
1-methyl-4-phenylpyridinium were reduced by 89 to 98%. The apparent
Km values were also decreased (choline by
15-fold, TEA by 8-fold,
N1-methylnicotinamide by 4-fold) or remained
constant (1-methyl-4-phenylpyridinium). After the mutation, the
membrane potential dependence of the Km value for [3H]choline uptake was abolished. The affinity
of n-tetraalkyl ammonium compounds to inhibit TEA uptake
was increased. This affinity and its increase by the D475E mutation
were increased with the length of the n-alkyl chains.
After expression in X. laevis oocytes, the
IC50 ratios of wild-type and D475E mutant were 1.7 (tetramethylammonium), 4.3 (TEA), 5.0 (tetrapropylammonium), 5.0 (tetrabutylammonium), and 65 (tetrapentylammonium). Cationic inhibitors
with ring structures were differentially affected: the IC50
value for TEA inhibition by cyanine 863 remained unchanged, whereas it
was increased for quinine. The data suggest that rOCT1 contains a large
cation-binding pocket with several interaction domains that may be
responsible for high-affinity binding of structurally different cations
and that Asp475 is located close to one of these interaction domains.
| |
Introduction |
|---|
|
|
|---|
A
variety of polyspecific transporters responsible for excretion and
reabsorption of drugs have been identified in eukaryotic plasma
membranes. In addition to the P-glycoproteins (multidrug resistant) and multidrug resistance proteins, which are primary active export pumps (Fykse and Fonnum, 1991
; Leier et al., 1994
; Müller and Jansen, 1997
), three families of polyspecific import transporters have been identified: the proton-peptide symporters (Meredith and Boyd, 1995
), a family containing different organic anion
transporters and the prostaglandin transporter (Kanai et al., 1995
;
Saito et al., 1996
; Müller and Jansen, 1997
), and the OCT1
family, which contains polyspecific cation and anion transporters
(Koepsell, 1998
; Koepsell et al., 1999
). In 1994, we cloned rOCT1
(Gründemann et al., 1994
), a transporter expressed in the
basolateral membrane of hepatocytes (Meyer-Wentrup et al., 1998
) and
renal proximal tubules (unpublished data), which is responsible for the
first step in hepatic and renal cation excretion. This transporter
mediates the electrogenic uptake of a variety of small organic cations,
including many cationic drugs, choline, and monoamine
neurotransmitters, and operates independently of sodium ions and proton
gradients (Busch et al., 1996a
,b
). rOCT1 may translocate small cations
in both directions, whereas large organic cations, such as quinine and
cyanine 863, are high-affinity transport inhibitors but are themselves
not transported (Nagel et al., 1997
). OCT2 and OCT3 transporters are
highly homologous subtypes of rOCT1 that operate in a similar fashion
(Koepsell et al., 1999
); these transporters are also electrogenic
transporters of small cations, including the monoamine
neurotransmitters, but they exhibit differences in substrate
specificity (Koepsell et al., 1999
). Another subgroup of the OCT1
family are the transporters OCTN1 and OCTN2, which translocate cations
and zwitterions (Tamai et al., 1997
; Wu et al., 1998
). OCTN2 mediates
Na+-dependent, high-affinity uptake of carnitine
(Tamai et al., 1998
), and gene defects in this transporter result in a
systemic carnitine deficiency in mice and humans (Nezu et al., 1999
).
It is of high medical significance that the molecular mechanism by
which polyspecific transporters translocate a variety of structurally
different substrates without losing substrate selectivity is
elucidated. The tertiary structure of polyspecific transporters is
unlikely to be resolved in the near future, so we attempted to mutate
amino acid residues in rOCT1 that may be involved in cation transport.
rOCT1 represents an ideal model because more than 20 members of the
OCT1 family have been cloned, including subfamilies that transport
zwitterionic or negatively charged substrates. This provides a good
basis to select amino acid residues for site-directed mutagenesis.
Previously cloned members of the OCT1 family share a common predicted
topology of 12 transmembrane
-helices (TM) and one large
extracellular loop between TM1 and TM2 (Koepsell et al., 1999
). We
decided to start our mutagenesis program by mutating glutamate and
aspartate residues because the involvement of acidic amino acids in the
translocation of cationic substrates has been demonstrated for
bacterial and mammalian transporters (Wilson and Wilson, 1992
;
Yamaguchi et al., 1992
; Pourcher et al., 1993
). The mammalian
transporters include the vesicular monoamine transporters (Merickel et
al., 1995
; Steiner-Mordoch et al., 1996
), the vesicular acetylcholine
transporter (Song et al., 1997
; Kim et al., 1999
), and the dopamine
transporter (Kitayama et al., 1992
). An amino acid sequence comparison
demonstrated that the electrogenic cation transporters (OCT1, OCT2, and
OCT3) contain six acidic amino acids that are conserved in neither the
OCTN-type transporters nor the anion transporters: two glutamate
(Glu68, Glu69) and two aspartate (Asp95,
Asp150) residues in the large extracellular loop, one aspartate
(Asp379) in TM8, and another (Asp475) in TM11. We began with the
mutation of Asp475, located in the middle of TM11. Replacement of
Asp475 by arginine, asparagine, and glutamate resulted in a significant
reduction in the transport rate. Interestingly, after the mutation of
Asp475 to glutamate, the affinity for specific cations was dramatically increased.
| |
Experimental Procedures |
|---|
|
|
|---|
Site-Directed Mutagenesis.
Mutants of rOCT 1 were
constructed using the polymerase chain reaction approach either
according to Chen and Przybyla (1994)
or by use of the overlap
extension method (Ho et al., 1989
). The mutagenic primers were 5'-T GCC
CTG TGT CGA CTG GGT GGG AT-3' (forward) for D475R, 5'-T GCC
CTG TGT AAC CTG GTG GG-3' (forward) and 5'-C ACC CAG
GTT ACA CAG GGC AG-3' (reverse) for D475N, and 5'-CC CTG
TGT GAG CTC GGT GGG ATC TT-3' (forward) and 5'-A GAT CCC
ACC GAG CTC ACA CAG GGC-3' (reverse) for D475E. Nucleotides corresponding to the mutated amino acid are underlined. The flanking primers were 5'-AGA CTG GCG CTG GCT CCA-3' (forward, position 817-834
of rOCT1) and 5'-GGT ACT TGA GGA CTT GCC-3' (reverse, position
1688-1705 of rOCT1). The polymerase chain reaction products were
digested with SauI and StyI, and a 520-bp
fragment was cloned into plasmid rOCT1/pRSSP (Busch et al., 1996b
) cut
with the same enzymes. The sequences of the cloned fragments were
verified by DNA sequencing.
Expression of rOCT1 in Oocytes of Xenopus laevis
and Transport Measurements.
The experiments with X. laevis oocytes were performed as described previously
(Gründemann et al., 1994
; Busch et al., 1996b
). Briefly, the
oocytes were stored in 5 mM 3-(N-morpholino)propanesulfonic acid-NaOH, pH 7.4, 100 mM NaCl, 1 mM MgCl2, 3 mM
KCl, and 2 mM CaCl2 (Ori buffer) containing 50 mg/liter gentamicin. Oocytes were injected with 10 ng of cRNA and
incubated for 2 or 3 days at 19°C in Ori buffer. For tracer uptake
measurements, oocytes were incubated for 60 min at 19°C in Ori buffer
containing radioactively labeled cations. The incubation was performed
in the absence and presence of 50 µM cyanine 863, and the
cyanine-inhibited uptake was calculated. The uptake of the analyzed
cations into the oocytes was linear during this time period. In some
measurements, sodium in the Ori buffer was replaced by potassium or
different concentrations of nonradioactive substrates or inhibitors
were added. The transport was stopped with ice-cold Ori buffer, and the
oocytes were washed four times with ice-cold Ori buffer, solubilized
with 100 µl of 5% (w/v) SDS, and analyzed for radioactivity.
Membrane potential measurements or two-electrode voltage-clamp
recordings in X. laevis oocytes were performed as described
previously (Nagel et al., 1997
). The oocytes were permanently
superfused with fresh Ori buffer at room temperature (3 ml/min). In
some experiments, NaCl was replaced by KCl to change the membrane potential.
Preparation of Plasma Membranes from X. laevis
Oocytes and Western Blot Analysis.
X. laevis oocytes
were injected with water (controls) or with 10 ng of cRNA of rOCT1,
D475R, D475N, or D475E and incubated for 3 days at 19°C. Half of the
oocytes were used for uptake measurements. The plasma membranes of the
other half of the oocytes (~60) were isolated through differential
centrifugations at 1,000g and 10,000g according
to Geering et al. (1989)
. For Western blot analysis, 3 to 6 µg of
isolated plasma membranes were incubated for 30 min at 37°C in 60 mM
Tris · HCl, pH 6.8, 100 mM dithiothreitol, 2% (w/v) SDS, and 7%
(v/v) glycerol; resolved by SDS-polyacrylamide gel electrophoresis;
transferred to nitrocellulose; and incubated with antibody raised
against the large extracellular loop of rOCT1 as described previously
(Meyer-Wentrup et al., 1998
). Reaction with the peroxidase-conjugated
secondary antibody (goat anti-rabbit IgG) was visualized by enhanced
chemiluminescence (ECL system; Amersham Buchler; Braunschweig,
Germany). Prestained molecular weight marker BenchMark (Life
Technologies, Karlsruhe, Germany) was used to determine apparent
molecular masses.
Transient Expression in Human Embryonic Kidney (HEK) 293 Cells. HEK 293 cells were grown in Dulbecco's modified Eagle's medium with 10% FCS, and the cells were transfected with the empty vector pRcCMV (InVitrogen, Groningen, the Netherlands) or with pRcCMV containing rOCT1, D475R, D475N, or D475E using the FuGENE 6 reagent from Boehringer-Mannheim Biochemica (Mannheim, Germany). When the cells became confluent 2 days after transfection, they were washed with PBS, suspended by shaking, collected by 10-min centrifugation at 1000g, and suspended at 37°C in PBS. For uptake measurements, the cells were suspended for 1 to 20 s with PBS (37°C) that contained either different concentrations of 1-[3H]methyl-4-phenylpyridinium ([3H]MPP) without and with 50 µM cyanine 863 or 0.1 µM [3H]MPP without and with different concentrations of tetrapentylammonium (TPeA). The uptake reactions were stopped with ice-cold PBS containing 100 µM quinine (stop solution), and the cells were washed three times by 5-min centrifugation with the ice-cold stop solution. In the stop solution, no significant cation efflux from the cells could be observed.
Calculations and Statistics. Indicated uptake rates from X. laevis oocytes represent medians from pairs of 8 to 10 oocytes ±S.E. values. The uptake rates determined in HEK 293 cells represent mean values from pairs of three or four determinations ±S.D. Apparent Km values were calculated by fitting the Michaelis-Menten equation to uptake measurements at different substrate concentrations. For calculation of IC50 values, the Hill equation for multisite inhibition was fitted to the data.
Materials.
[3H]MPP (2.2 TBq/mmol)
was provided by Biotrend (Köln, Germany). The other materials
were obtained as described previously (Busch et al., 1996b
)
| |
Results |
|---|
|
|
|---|
To elucidate the role of Asp475 in rOCT1 for the transport of
organic cations, we changed this residue to arginine (D475R), asparagine (D475N), or glutamate (D475E) and expressed the mutants in
X. laevis oocytes and HEK 293 cells. Oocytes were injected with 10 ng of cRNA, and the uptake rates of 10 µM
[14C]TEA and 0.1 µM [3H]MPP were determined in the
absence and presence of 50 µM cyanine 863. In one batch of oocytes,
the cyanine-inhibited uptake rates of TEA were 30.1 ± 3.8 (wild
type), 0.06 ± 0.08 (D475R), 0.32 ± 0.14 (D475N), 7.1 ± 2.8 (D475E), and 0.31 ± 0.05 (H2O) pmol · oocyte
1 · h
1.
The uptake rates in the presence of 50 µM cyanine were 0.03 ± 0.01 (wild type), 0.09 ± 0.03 (D475R), 0.09 ± 0.06 (D475N), 0.06 ± 0.03 (D475E), and 0.01 ± 0.01 (H2O)
pmol · oocyte
1 · h
1.
After transfection in HEK 293 cells, cyanine-inhibitable
[3H]MPP uptake could be expressed with all
three D475 mutants (Fig. 1). At variance
with wild-type rOCT1, cyanine-inhibited [3H]MPP
uptake in the mutants was linear for about 10 s. For 0.1 µM
[3H]MPP, cyanine-inhibited initial uptake rates
of 280 ± 10 (wild type), 15 ± 2 (D475R), 20 ± 1 (D475N), 22 ± 1 (D475E), and 4 ± 1 (empty pRcCMV
plasmid)
fmol · mg
1 · s
1
were determined. In the presence of 50 µM cyanine 863, the uptake rates were 25 ± 11 (wild type), 2.9 ± 0.9 (D475R), 8.8 ± 1.0 (D475N), and 3.0 ± 0.4 (D475E)
fmol · mg
1 · s
1.
To investigate whether the mutations disturb the insertion of rOCT1
into the plasma membrane, we probed Western blots with plasma membranes
isolated from X. laevis oocytes and reacted nonpermeabilized HEK 293 cells with an affinity-purified antibody against the large extracellular loop of rOCT1 (Meyer-Wentrup et al., 1998
). Different results were obtained with the two expression systems. Figure 2 shows Western blots of plasma membrane
fractions from oocytes that were developed with a specific antibody
against rOCT1. With wild-type rOCT1 and the D475R mutant, two
immunoreactive polypeptide bands with apparent molecular masses of 52 and 60 to 70 kDa were observed, which represent differentially
glycosylated transporter proteins (unpublished data). After expression
of the D475R and D475E mutants, greater protein amounts were observed
in the plasma membrane fraction than in the wild type, and the 60- to
70-kDa polypeptide was not detected in the D475E mutant (Fig. 2). In three independent experiments with different mRNA preparations and
oocyte batches, the D475N mutant could not be detected in the plasma
membrane fraction, although the cRNA of the D475N mutant was shown to
display a similar stability in the oocytes as wild-type cRNA. In
contrast to the oocyte experiments, immunohistochemistry with HEK 293 cells indicated that all three mutants were inserted into the plasma
membrane because the antibody against the large extracellular loop of
rOCT1 showed a significant reaction with nonpermeabilized cells
expressing the D475R, D475E, and D475N mutants (Fig.
3). No immunoreaction was observed with
vector-transfected control cells. On visual inspection of three
experiments, we did not distinguish differences in the immunoreaction
of transfected wild-type rOCT1 and the mutants.
|
|
|
To elucidate the functional role of Asp475, we compared functional
properties and substrate specificity of the D475E mutant with those of
the wild-type rOCT1. Because the Km values
are potential dependent (Busch et al., 1996b
) and the membrane
potential varies with different batches of X. laevis
oocytes, the functional characteristics of the D475E mutant and wild
type were compared within the same batches of oocytes. Figure
4 shows the substrate dependence of the
cyanine 863-inhibited uptake of TEA,
N1-methylnicotinamide (NMN), choline,
and MPP. Fitting the Michaelis-Menten equation to the data, the
following Km values were obtained for the
wild type and mutant, respectively: TEA, 129 ± 17 versus 16 ± 4 µM; NMN, 126 ± 20 versus 35 ± 5 µM; choline,
370 ± 120 versus 25 ± 7 µM; and MPP, 2.7 ± 1.1 µM
versus 2.2 ± 0.9 µM. The data indicate that the mutation of
Asp475 to glutamate leads to a significant decrease in
Km values of several small organic cations.
However, the Km value of the more bulky
cation MPP was not changed. In the D475E mutant, the
Vmax values for transport were drastically reduced compared with that of the wild type: to 2.3% for TEA, 3.2%
for NMN, 3.5% for choline, and 11.4% for MPP. The data show that the
D475E mutation alters the affinity for some of the transported cations.
|
Most bulky cations, such as quinine, d-tubocurarine, and
cyanine 863, are high-affinity inhibitors of rOCT1-mediated cation uptake but are not transported (Nagel et al., 1997
). Recently, we found
that TPeA belongs to this group of nontransported inhibitors and that
quinine, cyanine 863, and TPeA inhibited the uptake of [14C]TEA in a noncompetitive manner
(unpublished data). Because the D475E mutation apparently altered the
structure of the substrate binding site, we performed inhibition
experiments with transported cations and noncompetitive cationic
inhibitors to determine whether the D475E mutation has an effect on
both types of cationic interactions. To systematically investigate the
cation interaction, we measured the transport inhibition by
n-tetraalkyl ammonium compounds with increasing chain length
(Wright et al., 1995
). In Fig. 5, we
sought to determine the quaternary ammonium compounds that were
transported. When X. laevis oocytes expressing wild-type
rOCT1 clamped at
50 mV were superfused with saturating concentrations
(Fig. 6) of tetramethylammonium (TMA),
TEA, tetrapropylammonium (TPA), tetrabutylammonium (TBA), or TPeA,
significant rOCT1-mediated inward currents were detected only with TMA
and TEA. Because the TMA-induced current by rOCT1 increased with
increasing membrane potential (data not shown), we conclude that TMA is
also transported by rOCT1. The small inward currents observed with TPA,
TBA, and TPeA were similar to those observed with noninjected control
oocytes (Fig. 5). Thus, TPA, TBA, and TPeA do not mediate a significant
charge transport. These cations may be transported very slowly, without
netto translocation of electric charge, or they may be
nontransported inhibitors. Dose-response curves for inhibition of TEA
transport expressed by wild-type rOCT1 and the D475E mutant are shown
in Fig. 6. The affinity of the n-tetraalkyl ammonium
compounds increased with increasing alkyl chain length. In the wild
type, the IC50 values for inhibition decreased
from 1.3 ± 0.4 mM (TMA), 81 ± 9 µM (TEA), 12 ± 5 µM (TPA), and 3.0 ± 2.0 µM (TBA) to 0.53 ± 0.04 µM
(TPeA), and in the D475E mutant, the IC50 values
decreased from 0.78 ± 0.12 mM (TMA), 19 ± 5 µM (TEA),
2.4 ± 0.3 µM (TPA), and 0.6 ± 0.2 µM (TBA) to
0.008 ± 0.002 µM (TPeA). The n-tetraalkyl ammonium compounds had a higher affinity for the D475E mutant than for the wild
type, and the effect of the mutation increased with increasing alkyl
chain length: the ratios between the IC50 values
of the wild type and D475E mutant were 1.7 (TMA), 4.3 (TEA), 5.0 (TPA), 5.0 (TBA), and 65 (TPeA). Next, we compared the rOCT1 wild type and
D475E mutant for inhibition of TEA uptake by the noncompetitive inhibitors cyanine 863, quinine, and quinidine, which contain bulky
ring structures. Although the affinity of cyanine 863 was not changed
by the D475E mutation (Fig. 6; IC50 = 1.8 ± 0.6 µM for wild type and 2.0 ± 0.4 µM for D475E mutant), the
affinity of quinidine may be increased slightly
(IC50 = 4.2 ± 0.7 µM for wild type and
2.8 ± 0.5 µM for D475E mutant, difference not significant), and
the affinity of quinine was decreased (IC50 = 0.57 ± 0.04 µM for wild type and 1.3 ± 0.3 µM for D475E
mutant, P < .05). Thus, the D475E mutation impairs the
stereoselective interaction of quinine and quinindine with rOCT1 (Busch
et al., 1996b
).
|
|
Through measurement of choline-induced currents in rOCT1 expressing
voltage-clamped X. laevis oocytes, we previously observed that the choline concentrations required to induce half-maximal currents decreased at higher membrane potentials (Busch et al., 1996b
).
Because the low transport activity of the D475E mutant did not allow an
electrical analysis, we measured the substrate dependence of
[3H]choline uptake with 100 mM
Na+ in the bath and after replacement of
Na+ with K+; the membrane
potential decreased from
34 ± 3.9 mV (n = 5) to
13.6 ± 1.0 mV (n = 5). The apparent
Km value for cyanine-inhibitable choline
transport by rOCT1 increased from 0.23 ± 0.04 mM with sodium to
1.14 ± 0.23 mM after the replacement of sodium with potassium,
whereas the Vmax value was not changed
(Fig. 7a). In the D475E mutant, the
effect of the membrane potential on the Km
value was abolished: the apparent Km values
with sodium and potassium in the bath were 15 ± 3 and 17 ± 6 µM, respectively (Fig. 7b). At variance to wild-type rOCT1, the
Vmax value of choline transport expressed
by the D475E mutant was reduced in the presence of
K+. The data show that the potential dependence
of choline binding to rOCT1 is changed by the D475E mutation.
|
Next, we investigated whether specific effects of the D475E mutation on
cation affinity observed in the oocyte expression system could be also
detected when the transporter was expressed in mammalian epithelial
cells. In Fig. 8, we compared the
substrate dependence of [3H]MPP uptake into HEK
293 cells that were either transfected with wild-type rOCT1 or with the
D475E mutant. For cyanine-inhibited MPP uptake by wild-type rOCT1 and
by the D475E mutant, nearly identical Km
values of 9.4 ± 0.1 (wild type) and 9.3 ± 1.1 µM (D475E)
were obtained as has been observed in X. laevis oocytes. The
Km value for cyanine-inhibited MPP uptake
also was not changed significantly when Asp475 was replaced by arginine
or asparagine. For these mutants, Km values
of 5.8 ± 2.4 µM (D475R) and 10.6 ± 3.2 µM (D475N) were
determined. The differences between the Km
values after the expression of rOCT1 in X. laevis
oocytes or HEK 293 cells may be due to differences in intracellular
concentrations of endogenous cations or to different degrees of
post-translational modifications. The Vmax
values of cyanine-inhibited MPP uptake expressed by rOCT1 wild type and
D475E mutant were 12.1 ± 0.5 and 0.075 ± 0.003 pmol · mg
protein
1 · s
1,
respectively. This suggests that the turnover number for MPP transport
by rOCT1 is reduced by the D475E mutation.
|
We determined whether the affinity change for n-alkyl
ammonium compounds by the D475E mutation that was observed after
expression of the transporter in X. laevis
oocytes could be also detected in HEK 293 cells. Figure
9 shows rOCT1-mediated dose-response curves for the inhibition of [3H]MPP transport
by TPeA in these cells. For the initial cyanine-inhibited uptake rates
of [3H]MPP expressed by wild-type rOCT1 or by
the D475E mutant, IC50 values of 0.18 ± 0.04 and 0.018 ± 0.001 µM were determined, respectively. The
data show that the affinity increase by the D475E mutation can be
observed in different expression systems.
|
| |
Discussion |
|---|
|
|
|---|
The data indicate that Asp475 in the presumed 11th membrane
spanning
-helix of rOCT1 is important for cation selectivity. After
the expression of rOCT1 in HEK 293 cells, cation transport was largely
reduced when Asp475 was replaced by arginine, asparagine, or glutamate,
although similar amounts of transporter proteins were targeted to the
plasma membrane and a proper membrane insertion can be assumed because
the extracellular localization of the large loop between the first and
second presumed transmembranes was verified (Fig. 3). After expression
of the mutants in X. laevis oocytes, transport activity was
detected only with the D475E mutant. In the oocytes, the D475N mutant
was not targeted to the oocyte plasma membrane, whereas the D475R
mutation may not be folded properly. The differences observed with the
two expression systems are supposed to depend on differential
post-translational modifications or on different regulatory states of
the transporter. For example, the degree of glycosylation in the Golgi
complex may by influenced by the conformation of the transporter, which
may be stabilized by the binding of endogenous cations. Mutations in
the substrate binding site may abolish this effect and may be one
reason for changes in glycosylation. Recently, it was demonstrated that
the glycosylation of the human multidrug resistance P-glycoprotein is
highly dependent on the presence of intracellular substrates (Loo and
Clarke, 1999
).
Independent from the expression system, we observed that the functional
properties of rOCT1 were significantly changed when Asp475 was replaced
by glutamate, leading to an approximately 3 Å displacement of the
negatively charged carboxyl group from the
-helical backbone. This
mutation resulted in a significant affinity increase for some
transported cations (shown for TEA, NMN, and choline in oocytes),
whereas the affinity of other transported cations (shown for MPP in
oocytes and HEK 293 cells) remained unchanged. For wild-type rOCT1, the
rank order of apparent Km values was MPP
NMN = TEA < choline < TMA, whereas it was MPP < TEA < choline < NMN < TMA for the D475E mutant.
Thus, the selectivity of transported cations was changed. By the D475E
mutation, the Vmax value of MPP uptake
expressed in HEK 293 cells was reduced by 94%. Because our
immunohistochemical data revealed similar amounts of wild-type rOCT1
and D475E mutant in the plasma membrane and the
Km value for MPP was not changed, the
turnover for MPP is probably reduced in this mutant. By the D475E
mutation, a similar reduction of the Vmax
for MPP uptake was observed in oocytes (by 89%) as in HEK 293 cells
(by 94%). This suggests that the D475E mutant is properly targeted and
folded in the oocytes. Interestingly, in the oocytes, the
Vmax values for uptake of TEA, NMN, and
choline by the D475E mutant were reduced by 97 to 98%, which is
significantly more than the Vmax of MPP
uptake. This suggests that the increased affinity of these cations
leads to an impaired intracellular cation release that slows down the
transport rate.
The organic cation transporter is a facilitated diffusion system for
cations that may operate in both directions and can be driven by
chemical cation gradient and/or the membrane potential (Busch et al.,
1996b
, 1998
). According to current transporter models, substrate
binding to an outwardly directed site may induce a conformational
change in the transporter that makes the cation binding site accessible
to the cytosol. Our data show that the mutation of Asp475 to glutamate
alters the structure of the cation binding site and impairs the
translocation step. This can be concluded from the observation that the
Vmax value for MPP transport was reduced,
although the Km value was not changed. We
cannot distinguish whether Asp475 is localized within the cation
binding site and transport pathway or whether Asp475 helps to shape
these functional important transporter regions by stabilizing their
tertiary structures. The observations that the affinity of rOCT1 for a
variety of cations is increased by the D475E mutation and that the
affinity increases with the alkyl chain length strongly suggest that
Asp475 is localized close to the cation binding site because it is very
unlikely that such distinct effects result from a long-range
conformational effect induced by a conservative point mutation. Thus,
our data suggest either that Asp475 is located within the transport
pathway at the cation binding site or that Asp475 is located at a
nearby protein domain and stabilizes the conformation of the cation
binding site through an ionic interaction with another intramembraneous protein domain. The finding that the mutation of Asp475 to glutamate impairs the potential dependence of the Km
value for choline transport further strengthens the functional
importance of this amino acid residue. Further investigations are
required to elucidate whether cation binding or cation release is
potential dependent and which step during cation translocation is
influenced by the membrane potential.
The organic cation transporters rOCT1, rOCT2, and rOCT3 translocate a
variety of small cations and are inhibited by larger, more hydrophobic
cations, such as quinine, cyanine 863, decynium, and TPeA (Nagel et
al., 1997
; Koepsell et al., 1999
; present article). Recently, we showed
that quinine, cyanine 863, decynium 22, and TPeA inhibit
[14C]TEA uptake expressed by rOCT1 or rOCT2 in
a noncompetitive manner (unpublished data). The observation that the
D475E mutation in rOCT1 not only increases the affinity of transported
cations but also increases the affinity of the noncompetitive inhibitor
TPeA strongly suggests that transported and inhibitory cations interact at the same binding site because a point mutation should not alter the
cation affinity of two different binding sites in the same way. The
noncompetitive type of inhibition observed with the high-affinity inhibitors may be explained by a tight interaction of the hydrophobic high-affinity cations with several attachment domains at a polyvalent cation binding pocket. Such a type of polyvalent interaction may not
allow the replacement of large cations by smaller cations, which may
interact with only part of the attachment domains. This hypothesis may
also explain why the affinity of the low-affinity cation TMA and of the
high-affinity cations MPP and cyanine 863 are not changed by the D475E
mutation. These cations may interact with attachment domains of the
cation binding pocket that are not affected by the D475E mutation. It
is a challenge to determine the amino acid residues that contribute to
the cation binding site of rOCT1 and to detect mutations in humans by
which the excretion of organic cations is impaired and/or the
selectivity of excreted drugs is changed.
| |
Footnotes |
|---|
Received May 24, 1999; Accepted August 20, 1999
1 V.G. and C.V. contributed equally to the work.
This work was supported by Deutsche Forschungsgemeinschaft Grant SFB 174/A22.
Send reprint requests to: Prof. Dr. Hermann Koepsell, Anatomisches Institut der Universität, Koellikerstrasse 6, D-97070, Würzburg, Germany, E-mail: anat010{at}mail.uni-wuerzburg.de
| |
Abbreviations |
|---|
TM, transmembrane
-helix;
HEK, human
embryonic kidney;
TMA, tetramethylammonium;
TEA, tetraethylammonium;
TPA, tetrapropylammonium;
TBA, tetrabutylammonium;
TPeA, tetrapentylammonium;
MPP, 1-methyl-4-phenylpyridinium;
NMN, N1-methylnicotinamide.
| |
References |
|---|
|
|
|---|
-aminobutyrate and L-glutamate into synaptic vesicles. Effect of different inhibitors on the vesicular uptake of neurotransmitters and on the Mg2+-ATPase.
Biochem J
276:
363-367.
-subunit in the expression of functional Na+-K+-ATPase in Xenopus oocytes.
Am J Physiol
257:
C851-C858This article has been cited by other articles:
![]() |
K.-i. Umehara, M. Iwai, Y. Adachi, T. Iwatsubo, T. Usui, and H. Kamimura Hepatic Uptake and Excretion of (-)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans Drug Metab. Dispos., June 1, 2008; 36(6): 1030 - 1038. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gorbunov, V. Gorboulev, N. Shatskaya, T. Mueller, E. Bamberg, T. Friedrich, and H. Koepsell High-Affinity Cation Binding to Organic Cation Transporter 1 Induces Movement of Helix 11 and Blocks Transport after Mutations in a Modeled Interaction Domain between Two Helices Mol. Pharmacol., January 1, 2008; 73(1): 50 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sturm, V. Gorboulev, D. Gorbunov, T. Keller, C. Volk, B. M. Schmitt, P. Schlachtbauer, G. Ciarimboli, and H. Koepsell Identification of cysteines in rat organic cation transporters rOCT1 (C322, C451) and rOCT2 (C451) critical for transport activity and substrate affinity Am J Physiol Renal Physiol, September 1, 2007; 293(3): F767 - F779. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Rizwan, W. Krick, and G. Burckhardt The Chloride Dependence of the Human Organic Anion Transporter 1 (hOAT1) Is Blunted by Mutation of a Single Amino Acid J. Biol. Chem., May 4, 2007; 282(18): 13402 - 13409. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Pelis, Y. Dangprapai, T. M. Wunz, and S. H. Wright Inorganic mercury interacts with cysteine residues (C451 and C474) of hOCT2 to reduce its transport activity Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1583 - F1591. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Pelis, X. Zhang, Y. Dangprapai, and S. H. Wright Cysteine Accessibility in the Hydrophilic Cleft of Human Organic Cation Transporter 2 J. Biol. Chem., November 17, 2006; 281(46): 35272 - 35280. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Michel, Z. Yuan, S. Ramsubir, and M. Bakovic Choline Transport for Phospholipid Synthesis. Experimental Biology and Medicine, May 1, 2006; 231(5): 490 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, N. V. Shirahatti, D. Mahadevan, and S. H. Wright A Conserved Glutamate Residue in Transmembrane Helix 10 Influences Substrate Specificity of Rabbit OCT2 (SLC22A2) J. Biol. Chem., October 14, 2005; 280(41): 34813 - 34822. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Schmitt and H. Koepsell Alkali Cation Binding and Permeation in the Rat Organic Cation Transporter rOCT2 J. Biol. Chem., July 1, 2005; 280(26): 24481 - 24490. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ciarimboli, H. Koepsell, M. Iordanova, V. Gorboulev, B. Durner, D. Lang, B. Edemir, R. Schroter, T. Van Le, and E. Schlatter Individual PKC-Phosphorylation Sites in Organic Cation Transporter 1 Determine Substrate Selectivity and Transport Regulation J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1562 - 1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Popp, V. Gorboulev, T. D. Muller, D. Gorbunov, N. Shatskaya, and H. Koepsell Amino Acids Critical for Substrate Affinity of Rat Organic Cation Transporter 1 Line the Substrate Binding Region in a Model Derived from the Tertiary Structure of Lactose Permease Mol. Pharmacol., May 1, 2005; 67(5): 1600 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gorboulev, N. Shatskaya, C. Volk, and H. Koepsell Subtype-Specific Affinity for Corticosterone of Rat Organic Cation Transporters rOCT1 and rOCT2 Depends on Three Amino Acids within the Substrate Binding Region Mol. Pharmacol., May 1, 2005; 67(5): 1612 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Burckhardt Polyspecific Organic Cation Transport: Insights into the Substrate Binding Site Mol. Pharmacol., May 1, 2005; 67(5): 1391 - 1392. [Abstract] [Full Text] [PDF] |
||||
|
|